SHARE: Simple HAART With Abacavir, Reyataz, and Epivir

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2007 by Clinical Alliance for Research & Education - Infectious Diseases, LLC..
Recruitment status was  Recruiting
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
Clinical Alliance for Research & Education - Infectious Diseases, LLC.
ClinicalTrials.gov Identifier:
NCT00426296
First received: January 23, 2007
Last updated: October 30, 2007
Last verified: October 2007

January 23, 2007
October 30, 2007
August 2006
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00426296 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
SHARE: Simple HAART With Abacavir, Reyataz, and Epivir
An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks

SHARE: Simple HAART with Abacavir, Reyataz, and Epivir

Open-label, multicenter study of ABC/3TC + ATV in subjects who have completed at least 24 weeks of treatment on ABC/3TC+ATV/RTV as their first line regimen and have plasma HIV-1 RNA <50 copies/mL at entry

Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • HIV Infections
  • Lipodystrophy
  • Drug: atazanavir (Reyataz)
  • Drug: ritonavir (Norvir)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir (Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen
  • Viral load <50 copies/ml

Exclusion Criteria:

  • Viral load >50 copies/ml
  • Having taken more than one antiretroviral regimen
Both
18 Years and older
Not Provided
Contact: Richard A. Elion, MD drrelion@aol.com
United States
 
NCT00426296
COL102060
Not Provided
Not Provided
Clinical Alliance for Research & Education - Infectious Diseases, LLC.
GlaxoSmithKline
Principal Investigator: Richard A Elion, MD Whitman-Walker Clinic
Clinical Alliance for Research & Education - Infectious Diseases, LLC.
October 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP